- Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (the TRAFFIC study): a randomised trial. Lederman, R.J., Mendelsohn, F.O., Anderson, R.D., Saucedo, J.F., Tenaglia, A.N., Hermiller, J.B., Hillegass, W.B., Rocha-Singh, K., Moon, T.E., Whitehouse, M.J., Annex, B.H. Lancet (2002)